ライフサイエンスコーパス: chondroitin sulfate A

1 the actions of these two exolytic lyases on chondroitin sulfate A.

2 gh a process that does not involve PfEMP1 or chondroitin sulfate A.

3 (IEs) that surface-express VAR2CSA and bind chondroitin sulfate A.

4 parin > dermatan sulfate > heparan sulfate > chondroitin sulfate A.

5 basic peptides (FS2 and NFS3) to heparin and chondroitin sulfate A.

6 sulfatides, fucoidan, and heparin but not by chondroitin sulfate A.

7 R2CSA on their surface can bind to placental chondroitin sulfate A.

8 related to HS, but not by other GAGs such as chondroitin sulfate A and C, N-acetyl heparin and de-N-s

9 over dextran sulfate, dermatan sulfate, and chondroitin sulfate A and C.

10 turated, and saturated oligosaccharides from chondroitin sulfate A and chondroitin sulfate C, separat

11 arin, heparan sulfate, and dermatan sulfate; chondroitin sulfate A and hyaluronic acid were intermedi

12 Heparan sulfate and chondroitin sulfates A and C had no effect on activation

13 However, the glycosaminoglycans, chondroitin sulfate A, and dextran sulfate were potent i

14 alciparum adhesion to the placental receptor chondroitin sulfate A are associated with a reduced risk

15 f GAGs such as hyaluronic acid, heparin, and chondroitin sulfates A, B, and C induce arthritis, tendo

16 e-3-phosphate dehydrogenase aggregation, but chondroitin sulfates A, B, and C together with dextran s

17 inoglycans such as heparin, heparan sulfate, chondroitin sulfates A, B, and C, and sulfated compounds

18 ly folded PEDF bound to immobilized heparin, chondroitin sulfate-A, -B, -C, and dextran sulfate colum

19 Young ring-stage parasites derived from chondroitin sulfate A-binding isolates may also bind to

20 gh molecular weight (MW) dextran sulfate and chondroitin sulfate A, but not other anionic polysacchar

21 egulated when parasites are selected to bind chondroitin sulfate A, but other PfEMP1 forms may be upr

22 chondroitin better than dermatan sulfate and chondroitin sulfates A, C, D, and E, but it does not bin

23 lycan or with addition of heparan sulfate or chondroitin sulfate A/C but did stimulate BaF/KGFR divis

24 be our results of HC transfer experiments to chondroitin sulfate A, chemically desulfated chondroitin

25 Chondroitin sulfate, a common dietary supplement, increa

26 ing a unique pathway for depolymerization of chondroitin sulfate, a common GAG.

27 ed protein VAR2CSA and the glycosaminoglycan chondroitin sulfate A (CS) abundantly present in the int

28 Chondroitin sulfate A (CS-A, also known as chondroitin-4

29 tran sulfate (LDS) and the glycosaminoglycan chondroitin sulfate A (CSA) also had significant inhibit

30 tan sulfate (KS), dermatan sulfate (DS), and chondroitin sulfate A (CSA) and C (CSC), polymerized in

31 villous spaces of the placenta by binding to chondroitin sulfate A (CSA) and elicit inflammatory resp

32 EMP1 variant that binds to the host receptor chondroitin sulfate A (CSA) and is implicated in malaria

33 In pregnant women, VAR2CSA binds to chondroitin sulfate A (CSA) and mediates placental seque

34 erythrocytes (IEs) that selectively bind to chondroitin sulfate A (CSA) and sequester in placental t

35 ocytes that adhere to the placental receptor chondroitin sulfate A (CSA) and sequester in the placent

36 ciparum-infected erythrocytes, and placental chondroitin sulfate A (CSA) are primarily responsible fo

37 d erythrocytes adhering in the placenta bind chondroitin sulfate A (CSA) but not CD36.

38 (IEs) sequestration through cytoadhesion to chondroitin sulfate A (CSA) expressed on the surface of

39 ich mediates adherence of red blood cells to chondroitin sulfate A (CSA) in the placenta.

40 ress the surface antigen VAR2CSA and bind to chondroitin sulfate A (CSA) in the placenta.

41 Plasmodium falciparum VAR2CSA binds to chondroitin sulfate A (CSA) on the surface of the syncyt

42 hesion of parasites to the glycosaminoglycan chondroitin sulfate A (CSA) present on syncytiotrophobla

43 ncipal ligand associated with the binding to chondroitin sulfate A (CSA) that allows placental seques

44 alciparum-infected erythrocytes to placental chondroitin sulfate A (CSA) through the PfEMP1-VAR2CSA p

45 lay the variant surface antigen VAR2CSA bind chondroitin sulfate A (CSA) to sequester in placental in

46 m falciparum-infected erythrocytes adhere to chondroitin sulfate A (CSA) to sequester in the human pl

47 the surface of iRBC selected for adhesion to chondroitin sulfate A (CSA), a placental receptor for pa

48 glycans (GAGs) include keratan sulfate (KS), chondroitin sulfate A (CSA), and hyaluronic acid (HA).

49 igenically distinct and bind receptors, like chondroitin sulfate A (CSA), that are not commonly bound

50 hesion of VAR2CSA-expressing erythrocytes to chondroitin sulfate A (CSA)-a major criterion for evalua

51 serum cross-reacted with surface proteins of chondroitin sulfate A (CSA)-binding laboratory strains (

52 chia pastoris and developed a panel of seven chondroitin sulfate A (CSA)-binding parasites from diver

53 um-infected erythrocytes (PE) to immobilized chondroitin sulfate A (CSA)-conjugated albumin at a conc

54 responsible for binding to the placenta via chondroitin sulfate A (CSA).

55 2CSA, a parasite antigen that interacts with chondroitin sulfate A (CSA).

56 ythrocytes (IEs) with the ability to bind to chondroitin sulfate A (CSA).

57 ns (VSA) expressed on the surface of pRBC to chondroitin sulfate A (CSA).

58 dichotomously to the host receptors CD36 and chondroitin sulfate A (CSA).

59 and an erythrocyte-surface ligand that binds chondroitin sulfate A (CSA-L) have been implicated.

60 major glycosaminoglycans, including heparin, chondroitin sulfate A, dermatan sulfate, and OSCS.

61 ed multivariate analysis, including heparin, chondroitin sulfate A, dermatan sulfate, and the infamou

62 d, partially sulfated, or fully oversulfated chondroitin sulfate A, dermatan sulfate, or heparan sulf

63 variant surface antigen that binds placental chondroitin sulfate A, have been suggested to mediate pr

64 escribes the separation of dermatan sulfate, chondroitin sulfate A, heparin, and the semisynthetic fu

65 SA expressed on infected red blood cells and chondroitin sulfate A in an in vitro binding-inhibition

66 the variant surface antigen PfEMP1 that bind chondroitin sulfate A in vitro (PfEMP1(varCSA)) are high

67 Chondroitin sulfate A, in contrast, inhibited gB2 bindin

68 of Hic to hTSP-1 is inhibited by heparin and chondroitin sulfate A, indicating binding to the N-termi

69 nfected erythrocytes and mediates binding to chondroitin sulfate A, initiating inflammation and disru

70 e antigen VAR2CSA (variant surface antigen 2-chondroitin sulfate A) is expressed on infected erythroc

71 The results for chondroitin sulfate A, isolated from bovine trachea, are

72 thereby promoting amyloid formation, whereas chondroitin sulfate A kinetically traps partially unfold

73 otein associated with PM called P falciparum chondroitin sulfate A ligand (PfCSA-L).

74 Second, C1INH bound to host CD36 and chondroitin sulfate A molecules, interfering with cytoad

75 isolates of P. falciparum uniformly bind to chondroitin sulfate A on the syncytiotrophoblast.

76 Chondroitin sulfate A, on the other hand, showed a stron

77 ent, as certain sulfated hexosamines tested (chondroitin sulfates A or B) were ineffective.

78 lfate, and chondroitin sulfate B, but not by chondroitin sulfates A or C, or hyaluronic acid.

79 he presence of the contaminant, oversulfated chondroitin sulfate A (OSCS), in heparin.

80 Attachment was inhibited by chondroitin sulfate A, suggesting that it was mediated b